Previous 10 | Next 10 |
Net cash used in operating and investing activities was $23.2 million in the first quarter; quarter-end cash and restricted cash position of $355.4 million provides funding to advance a broad pipeline DUBLIN, Ireland, May 06, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRT...
DUBLIN, Ireland, April 29, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its first quarter of 2020 financial results on Wednesday, May 6, 2020, after the close of ...
DUBLIN, Ireland, April 24, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today announced a change in the location of its annual general meeting of shareholder scheduled to be held on Tuesday, May 19, 2020. The meeting will convene as scheduled at The Merrion Hotel, Upper M...
PAVmed Receives FDA Approval for Carpal Tunnel Device PAVmed ( PAVM ) reported that the FDA has given its approval for its CarpX device. It is a single use tool which is used for treating carpal tunnel syndrome and is minimally invasive. With this approval, PAVmed may now market the produc...
The global Covid-19 outbreak has shaken up a lot of things, but Roche ( OTCQX:RHHBY ) continues on with a steady growth trajectory. While there have been some disruptions to a few drug franchises, and there could be more of an impact in the second quarter, the outbreak has also been a time f...
Roche Holding (OTC: RHHBY) grew sales by 2% year over year in the first quarter, but the results were affected by the weaker Swiss franc, the currency in which the Swiss pharmaceutical company reports its profits and losses. On a constant currency basis, sales were up a more promising 7% y...
Thinly traded micro cap Prothena ( PRTA -16.3% ) slumps out the gate this morning on the heels of an update from licensee Roche ( OTCQX:RHHBY ) on a Phase 2 clinical trial, PASADENA , evaluating prasinezumab in patients with early Parkinson's disease (PD). More news on: Prothena Corpo...
DUBLIN, Ireland, April 22, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced that today Roche provided an update on Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early P...
DUBLIN, Ireland, April 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that in connection with hiring an executive on March 30, 2020, the compensation committee of the Companyȁ...
DUBLIN, Ireland, March 31, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s d...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...